Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Abrams

Showing results (321-330 of 367) with videos related to

Pageof 37
Sort By:
Oncotarget|July 7, 2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyMelissa L Sokolosky, Kristin M Stadelman, William H Chappell, et al.
Leukemia|August 8, 2008
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistanceJ A McCubrey, S L Abrams, G Ligresti, et al.
Advances in Biological Regulation|December 6, 2021
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53Stephen L Abrams, Shaw M Akula, Linda S Steelman, et al.
Leukemia|March 14, 2008
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemiaL S Steelman, S L Abrams, J Whelan, et al.
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Cell Cycle (Georgetown, Tex.)|August 27, 2011
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cellsLinda S Steelman, Patrick Navolanic, William H Chappell, et al.
Nature Materials|April 26, 2011
Bioinspired molecular co-catalysts bonded to a silicon photocathode for solar hydrogen evolutionYidong Hou, Billie L Abrams, Peter C K Vesborg, et al.
Cells|March 10, 2022
Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53Stephen L Abrams, Przemysław Duda, Shaw M Akula, et al.
Leukemia|March 26, 2011
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathwayA M Martelli, C Evangelisti, W Chappell, et al.
Leukemia|June 20, 2013
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic interventionJ A McCubrey, L S Steelman, F E Bertrand, et al.
Pageof 37

Showing results (321-330 of 367) with videos related to

Sort By:
Pageof 37
Oncotarget|July 7, 2011
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapyMelissa L Sokolosky, Kristin M Stadelman, William H Chappell, et al.
Leukemia|August 8, 2008
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistanceJ A McCubrey, S L Abrams, G Ligresti, et al.
Advances in Biological Regulation|December 6, 2021
Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53Stephen L Abrams, Shaw M Akula, Linda S Steelman, et al.
Leukemia|March 14, 2008
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemiaL S Steelman, S L Abrams, J Whelan, et al.
Aging|April 27, 2022
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic propertiesJames A McCubrey, Akshaya K Meher, Shaw M Akula, et al.
Cell Cycle (Georgetown, Tex.)|August 27, 2011
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cellsLinda S Steelman, Patrick Navolanic, William H Chappell, et al.
Nature Materials|April 26, 2011
Bioinspired molecular co-catalysts bonded to a silicon photocathode for solar hydrogen evolutionYidong Hou, Billie L Abrams, Peter C K Vesborg, et al.
Cells|March 10, 2022
Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53Stephen L Abrams, Przemysław Duda, Shaw M Akula, et al.
Leukemia|March 26, 2011
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathwayA M Martelli, C Evangelisti, W Chappell, et al.
Leukemia|June 20, 2013
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic interventionJ A McCubrey, L S Steelman, F E Bertrand, et al.
Pageof 37